In an aitempt to find tbt ospthad single tierrpcoOic dose of fenoterol 
Thirteen patients (eight male and five female) had diagnoses of bronchial asthma, and three (one male and two female) had chronic bronchitis according to the criteria of the American llumcic Society clasdcation.1~ The latter three patients could be classified as having asthmatic bronchitis. None had histories of cardiac, bepatic, renal, or metabolic disease or hyperh&n Patients receiving steroid medication were allowed to enter the study only when their conditions had been stabilized by minimal maintenance doses equivalent to less than 10 mg of prednisone daily for at least four weeks before the study. Fcmr of the patients had been taking beckmethasone inhalant (Vanceril), two whiffs four times a day, and five were taking both p d d s o m and V a n d . In these patients prednisone therapy was switched from singta morning to single evening doses ten days before their first visit.
Steroid inhalant therapy was modified to three times a day on test days without changing the total number of whiflFs and starting the k t dose at the conclusion of the test Two of the patients with asthmatic bronchitis were cigarette smokers. They were not allowed to smoke for at least two hours before reporting to the pahmonary laboratory and for the duration of the testing period.
Each patient was studied at the same dme of day (AM) at two-to three-day intervals for a total of seven visits. On test days, all short-acting bran-rs and sympathomimetic drugs had been excluded for at least eight hours, and all longacting bronchodilators and antihistamines for at least 12 hours before the start of and for the duration of the testing. Steroid medications were also withheld for at least eigbt hours before the testing and during the te.sting period. In those patients taking steroid medication, daily dosage was not changed throughout the study period.
Test Drugs und Dbsa
After the baseline evaluations, one of the following doses of the solution test drug was given on each study day: fenoterol ( Th 1165a) solution: 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg; fenoterol metered dose inhalant: 2 whiffs (= 0.4 mg), or placebo solution: distilled water. The placebo and fenoterol solutions were administered in a double-blind, crossover fashion. Fenoterol solution of tbe test doses were prepared in 2-ml plastic syringes from an 0.5 percent fenoterol stock solution. The placebo solution was prepared in the same manner.
All of these doses except the fenoterol metered dose inhalant were administered by nebulization with a motordriven, handbeld nebulizer (Maxi Myst nebulizer, Mead Johnson Laboratories, Evansville, Ind).
The patients were instructed to inhale the test drugs from functional residual capacity (FRC) to near total lung capacity (TLC) and to hold their breath for a few seconds at the end of the inhalation. The nebulization is made only when a small hole on the nebulizer is closed by a fmger so that there is no loss of the test drug into the atmosphere. Patients were allowed to have a light breakfast before reporting to the pulmonary laboratory and to eat a light lunch immediately after the third hour af testing.
Pulmonary Function Studies
In the morning of each test day, body pkhysmography *Each patient signed a consent form approved b the institutional committee on human rraaarch aftex expLtion of his role in the study.
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followed by spirometry were performed before the inhalation of the test drugs (baseline study). the^ measurements were repeated at 35 ( spirometry only), % (spinmetry only), 1, patients tolerated up to and including three-hour periods, only 11 of them remained in the study at the end of the eight-hour study protocol as shown in Table 2 . Table 1 shows the average baseline values of pul- the drug administration.
Pulmonary Function Data for Fenoterol up Placebo
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The trend of the dose-response relations over the eight hour course was similar for all the functional variables except for FRC. Although maximal response was not necessarily achieved by the highest test dose, both magnitude and duration of response were generally dose-dependent.
When the duration of drug action is evaluated by comparing the response to the placebo with those of the test doses, all doses of fenoterol produced a significant increase over placebo for eight hours from 15 minutes following the drug administration in FEVI and SGaw (Fig 1 and 3A) , whereas the duration of action is somewhat shorter in FEF25-% and FVC, lasting for six hours in most o f the test doses (Fig 2A and 2B) . When the duration of drug action is defined differently as a time interval that sustains a significany greater average FEVl over respective average baseline FEV1, it seems to be a dose-related phenomena (Table 2) . In this way, the placebo did not produce any significant change in FEVt over baseline at any test period, but the lower fenoterol doses (0.4 mg MDI and 0.5 mg) It should be noted in Figure 1 that there were significant differences in magnitude of response in FEVl between the highest dose (2.5 mg) and the lowest dose (0.4 mg ) from two-hour to six-hour periods and between 2.0 mg and 0.4 mg at onehour periods when the response to 2.0 mg exceeded 2.5 mg. Differences in response among other test doses did not reach significant levels at any time periods. In SGaw (Fig 3A) , responses to 2.5 mg were significantly greater than those to 0.4 mg MDI from three-hour to six-hour time periods, but at one-and two-hour periods, responses to 1.0 mg exceeded 2.5 mg and were significantly greater than responses to 0.4 mg MDI. It should also be noted in Figures 1 to 3 that the magnitude of response to 1.0 mg was consistently greater than responses to the lower doses (0.4 mg MDI, and 0.5 mg ) from 15 minutes to six-hour time periods in all the functional parameters except for FVC, and that 1.0 mg exceeds in response to 2.0 mg in SG,,, and to 1.5 mg in FEVt and FEF-75 up to sixdhow periods, although the difFerences in magnitude of response between 1.0 mg and these two test doses were not statistically significant. In FEFs~J and FVC, differences in response between higher doses and lower doses were less obvious than in FEVl and SGaw, and only at a few time periods (at 15 min, 30 min, and one hour in F E F~s -~~ at four hours and five hours in N C ) did the Merences reach significant levels. In FRC (Fig 3B) , a dose-response relation was not apparent, although all doses of the test drug reduced the size of FRC to a significant degree compared to placebo for at least six hours and five of the six doses for eight hours. Results of a comparison of 1.0 mg fenoterol to 1.0 mg isoproterenol in ten patients are presented in Figure 4 . Fenoterol sustained a highly significant increase in FEVl over placebo from 30 minutes to three hours after administration of the drug, whereas isoproterenol produced a significant effect for only one hour. The magnitude of response with fenoteml was sigplficantly greater than isoprotereno1 at one-, two-, and three-hour time periods.
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-the drug action over their baseline for three hours and 1.0 mg, 1.5 mg, and 2.0 mg did for four hours
Hewt Rate and Blood Pressure
There were no significant differences in average heart rate or systolic or diastolic blood pressure from the respective mean baseline values during the eight-hour test periods on any of the test doses and the placebo. However, the higher doses of I 2 3 fenoterol (1.5, 2.0, and 2.5 mg) tended to increase the heart rate slightly within the first hour and -10-TIME, hours decrease both systolic and diastolic blood pressures baseline level in two hours after lunch, and decreased slowly again afterward The lower doses (0.4 mg MDI, and 0.5 mg, and 1.0 mg) followed a similar pattern of change to the placebo with smaller magnitudes of change. With the higher doses ( 1.5 mg, 2.0 mg and 2.5 mg) of fenoterol, the mean heart rate increased by 2.4 beats/& (3.0 percent ) to 7.4 beats/ min (9.1 percent) in 30 minutes to one hour and returned to their baseline levels at two-hour periods; thereafter, patterns of change were similar to the placebo.
following inhalation of the lower doses of fenoterol and the placebo.
Subfecttoe Adverse Eflects
The number of patients reporting adverse effects during the eight-hour test periods is summarized in Table 3 . Most of these side effects were of mild degree, transient, and tended to occur within 30 minutes after drug administration and disappear after 30 minutes to one hour. The most common adverse effect was tremor or shakiness of hands, which appeared to be dose-related None of the patients had to terminate the study because of these side effects.
Previous reports have shown that aerosolized fenoterol is a potent and long-acting bronchodilator, and one-to two-puffs from a MDI (0.2, 0.4 mg) has been recommended as a single therapeutic dose.2d*~1s*15 The results of the present study have c o h e d these findings, and have shown that inhaled fenoterol w& a far more potent and longacting bronchodilator than inhaled isoproterenol in dose-bydose comparison.
Significant bronchodilation' as evaluated by spirometric and body plethysmographic measurements was observed at less than 15 minutes following administration of fenoterol, and the effect lasted for The greatest change in the mean systolic and about eight hours compared to placebo in all the diastolic blood pressures were a decrease of 4.4 test doses including the lowest dose (0.4 mg) demm H g and 5.0 mm Hg, which occurred at twolivered from MDI. Although significant airway rehour and 30-minute periods, respectively, following sponses were seen in all the functional parameters, inhalation of 2.5 mg of fenoterol. There was no the time to reach peak responses was greater and consistent trend m the change in blood pressures the duration of the drug action was shorter in Although the MDI is a convenient and popular way to deliver bronchodilators, there are certain circumstances that administration by devices other than MDI, such as the compressor-powered nebulization system (CPN) used in this study, are preferred as recommended by Posey and Ti~kelman.~ Examples of such are patients who have an adverse reaction to Freon propellant or who have a tendency to abuse MDI. Little information concerning the optimal therapeutic dose of fenoterol solution for use with CPN has been available. In this study, the test doses were chosen on the basis of the previous knowledge that when bronchodilator is delivered by IPPB (Bud Mark 7 respirator and nebulizer), only 10 to 15 percent of nebulized dose reaches the lung, and the remainder is retained in the mouthpiece, nebulizer, tubings, and the expired air. When admhistered from a pressurized canister, nearly all of the dose is retained by the patient.* In accordance with this, Weber et alH found that when terbutaline was administered by both IPPB and CPN, six to eight times as much drug was required to achieve the same degree of bronchodilation as when administered from MDI. In the present study, therefore, five test doses of fenoterol sohtion, ranging from 1.25 to 6.25 times the recommended therapeutic dose from MDI (0.4 mg) were administered by CPN. Contrary to the previous studies, the results of this study do not seem to indicate that much larger doses are required to achieve the same degree of functional improvement when delivered by CPN compared to the dose by MDI, since there was no signilkant diEerence in response between 0.4 mg of fenoterol from MDI and 0.5 mg by the CPN. This is probably due to one or both of the followmg: (1) there may have been only a negligible waste of the drug in the expired air and in the nebulization system used in the present study in which no tubing was placed distal to the nebulizer. Patients participating in this study had been well instructed in how to inhale the aerosol without wasting it into the atmosphere; and (2) the administration of the drug was made by multiple inhalations over a period of time that may have helped greater penetration of the drug into peripheral h a y s .
There has been no conclusive evidence to support that multiple inhalation of bronchodilator produces better results than a single inhalation of the same dose. Weber et ala compared the bronchodilator eflect of four inhalations of 0.125 mg of terbutaline (total dose = 0.5 mg) at one-minute intervals from a MDI to a single inhidation of the same dose (0.5 mg) in patients with bronchial asthma. They found that the mean response in FEVt to terbutaline as a sin& dose was consistently less than the response to terbutaline in divided doses, although the results did not reach a level of statistical significance. They suggested that the bronchodilator response is related to the total dose inhaled, not to the number of inhalations required to achieve that dose.
Most of the adverse reactions to fenoterol were very mild, transient, and well-tolerated phenomena and did not seem to be dose-related in the dose range tested except for a sensation of shakiness and tremor of the hands. The latter was the most frequent side efFect and seemed to be dose-related in terms of incidence and degree.
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From the results of the present study, we. 
